Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement

BACKGROUND/OBJECTIVES: Renaming non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) suggests a shift of emphasis to the accompanying metabolic disturbance. Controlled attenuation parameter (CAP) measured by FibroScan has been shown to be correlat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhimin, Ng, Kaka, Chen, Hongyan, Deng, Wanping, Li, Yanbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841525/
https://www.ncbi.nlm.nih.gov/pubmed/35173677
http://dx.doi.org/10.3389/fendo.2021.739875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841525/
https://www.ncbi.nlm.nih.gov/pubmed/35173677
http://dx.doi.org/10.3389/fendo.2021.739875

Ejemplares similares